Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and Antibody drug Conjugates (ADCs). Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.
Products, services, technology
Enantios (https://enantios.com/) offers in-solution Raman and Raman Optical Activity (ROA) measurement systems that provide detailed structural and conformational insights into 3D structure, chirality and macromolecules and ADCs coformation.
Cooperation possibilities
With strong traction in academia and pharmaceuticals, we are scaling our technology to drive innovation in global healthcare and advanced materials research. We welcome collaborations with Pharma, Agrochemical, cosmetics and food industry as well as ADCs (antibody-drug-conjugate) and macromolecules.
- https://enantios.com/
- +44 779 695 16 25
- Send an email
- Alessia Portieri
Some insights
Enantios enables fast, non-destructive analysis of complex chiral molecules—like antibody-drug conjugates—advancing drug discovery and quality control to improve patient outcomes and accelerate innovation in life sciences, agrochemical and food industry.
Enantios brings cutting-edge, label-free chiral analysis to life sciences—making it easier to understand complex molecules like ADCs, solve hard analytical problems, and support breakthroughs in drug development diminishing the risk of drugs falling off the pipeline.
Companies like Tubulis who push boundaries in ADC development and make sure new technologies are adopted to improve drug development. They inspire innovation, integrity, and scientific impact.
Our team excels in spectroscopy, optics, instrument design, and problem-solving for complex molecular systems. We also have expertise in biopharma analytics, data science, and regulatory strategy to expand our impact in drug development and manufacturing.
They’d probably say, “Something with light and molecules—helping scientists figure out what’s in their medicines.” Not far off!
By facilitating access to biopharma partners for pilot studies, supporting funding for tech validation, and fostering visibility through biotech networks and events, the Swiss ecosystem can accelerate adoption of our analytical tools in drug development.
We’d like to connect with ADC developers, analytical scientists, QC leads, and innovation teams in biopharma—as well as collaborators in CROs and academic labs working on complex biologics or struggling with chiral or structural characterization challenges.